Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drug Toxicity: Dose-Dependent Reactions

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.

The New England journal of medicine·2026

Same author

Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy.

Stem cell reports·2026

Same author

IgG4-Related Disease Presenting With Diffuse Coronary Atherosclerosis Characterized by Marked Lipid-Rich Necrotic Core Burden.

JACC. Case reports·2026

Same author

Radiation reprograms fibroblasts to drive prostate cancer therapy resistance.

Endocrine-related cancer·2025

Same author

Corrigendum to 'Evaluating the mechanism of action behind controlled hypothermic preservation of donor hearts: A randomized pilot study' [J Heart Lung Transplant, 44 (2025) 1137-1145].

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025

Same author

Methods for detection of cardiac glycogen-autophagy.

Autophagy reports·2025

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy and cardiotoxicity.

Howard Broder¹, Roberta A Gottlieb, Norman E Lepor

¹Cedars-Sinai Medical Center, Los Angeles, California, USA.

Reviews in Cardiovascular Medicine

|July 29, 2008

Summary

Cancer treatments can cause heart problems, including heart failure and cardiomyopathy. Early monitoring for cardiac dysfunction is crucial to prevent severe outcomes in patients undergoing cancer therapy.

Area of Science:

Cardiology
Oncology
Pharmacology

Background:

Cancer therapies have significantly improved patient survival, leading to long-term survivorship.
Increased survival allows for the manifestation of adverse cardiovascular effects from cancer treatments.
Cardiotoxicity is an emerging concern in cancer care, impacting long-term patient health.

Purpose of the Study:

To review the cardiotoxic effects of common cancer therapies.
To highlight the clinical presentation and timing of chemotherapy-induced cardiac dysfunction.
To emphasize the importance of early detection and monitoring for cardiovascular complications in cancer patients.

Main Methods:

Literature review of cardiotoxicity associated with cancer therapies.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Analysis of reported cardiovascular adverse events linked to specific chemotherapy agents and targeted therapies.

Discussion of clinical manifestations, including acute, subacute, and late-onset cardiac dysfunction.

Main Results:

Anthracyclines are associated with acute myopericarditis and late-onset heart failure or cardiomyopathy.
5-Fluorouracil, capecitabine, and trastuzumab are also implicated in cancer treatment-related cardiotoxicity.
Cardiac dysfunction can occur acutely, months, or years after cancer therapy completion.

Conclusions:

Cardiotoxicity is a significant concern for long-term cancer survivors.
Aggressive monitoring for early signs of cardiac dysfunction is essential.
Preventative strategies and improved treatments for cardiotoxicity are needed to mitigate morbidity and mortality.